Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
IEEE Engineering in Medicine and Biology Magazine : the Quarterly Magazine of the Engineering in Medicine & Biology Society|April 8, 2009
Multiscale modeling of biomedical, biological, and behavioral systems (Part 1)Ronald White, Grace Peng, Semahat Demir
Risk Analysis : an Official Publication of the Society for Risk Analysis|November 3, 2010
Risk characterization for nanotechnologyRichard A Williams, Kristen M Kulinowski, Ronald White, et al.
Nature Communications|August 29, 2020
Charge and exciton dynamics of OLEDs under high voltage nanosecond pulse: towards injection lasingViqar Ahmad, Jan Sobus, Mitchell Greenberg, et al.
Anesthesiology|February 25, 2010
Incidence and root cause analysis of wrong-site pain management procedures: a multicenter studySteven P Cohen, Salim M Hayek, Sukdeb Datta, et al.
Risk Analysis : an Official Publication of the Society for Risk Analysis|September 18, 2010
Nano risk analysis: advancing the science for nanomaterials risk managementJo Anne Shatkin, Linda Carolyn Abbott, Ann E Bradley, et al.
JAMA Psychiatry|November 7, 2019
Effect of Stellate Ganglion Block Treatment on Posttraumatic Stress Disorder Symptoms: A Randomized Clinical TrialKristine L Rae Olmsted, Michael Bartoszek, Sean Mulvaney, et al.
Bioorganic & Medicinal Chemistry Letters|April 11, 2015
BMS-871: a novel orally active pan-Notch inhibitor as an anticancer agentWeifang Shan, Aaron Balog, Claude Quesnelle, et al.
ACS Medicinal Chemistry Letters|May 26, 2015
Discovery of Clinical Candidate BMS-906024: A Potent Pan-Notch Inhibitor for the Treatment of Leukemia and Solid TumorsAshvinikumar V Gavai, Claude Quesnelle, Derek Norris, et al.
Journal of Medicinal Chemistry|September 29, 2006
Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infectionSrikanth Venkatraman, Stéphane L Bogen, Ashok Arasappan, et al.
Environmental Health Perspectives|April 20, 2016
The Next Generation of Risk Assessment Multi-Year Study-Highlights of Findings, Applications to Risk Assessment, and Future DirectionsIla Cote, Melvin E Andersen, Gerald T Ankley, et al.
Pageof 1